RT Journal Article
SR Electronic
T1 The cellular hierarchy of acute myeloid leukemia informs personalized treatment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.24.24310768
DO 10.1101/2024.07.24.24310768
A1 Severin, Yannik
A1 Festl, Yasmin
A1 Benoit, Tobias M.
A1 Wegmann, Rebekka
A1 Hale, Benjamin D.
A1 Roiss, Michael
A1 Kienzler, Anne-Kathrin
A1 Pabst, Thomas
A1 Scharl, Michael
A1 Sunagawa, Shinichi
A1 Manz, Markus G.
A1 Müller, Antonia M.S.
A1 Snijder, Berend
YR 2024
UL http://medrxiv.org/content/early/2024/07/24/2024.07.24.24310768.abstract
AB Acute myeloid leukemia (AML) is characterized by malignant myeloid precursors that span a cellular hierarchy from dedifferentiated leukemic stem cells to mature blasts. While the diagnostic and prognostic importance of AML blast maturation is increasingly recognized, personalized therapies are currently not tailored to a patients individual makeup of this cellular hierarchy. In this study, we use multiplexed image-based ex vivo drug screening (pharmacoscopy) to systematically quantify the drug sensitivity across the cellular hierarchy of AML patients. We analyzed 174 prospective and longitudinal patient samples from 44 newly diagnosed AML patients, which indicated that differences in the AML hierarchy significantly identified poor responses to first-line therapy, outperforming European LeukemiaNet (ELN) criteria. Critically, drug response profiling across the AML hierarchy of each patient improved the accuracy of predicting patient response to first-line therapy (AUC 0.91), and revealed alternative individualized treatment options targeting the complete AML hierarchy of non-responding patients. We confirmed these findings in an independent cohort of 26 relapsed/refractory AML patients, for whom pan-hierarchy response profiling improved response predictions post hoc. Overall, our results quantify the clinical importance of therapeutically targeting the complete cellular hierarchy of newly diagnosed AML, and identify multiplexed image-based ex vivo drug screening to enable quantification and targeting of the AML maturation hierarchy for improved personalized treatment.Competing Interest StatementBerend Snijder was a scientific co-founder of Allcyte GmbH, which has been acquired by Exscientia; is a shareholder of Exscientia and a co-inventor on U.S. patent application 15/514,045 relevant to the study; declares research funding from Roche and speaker fees from Novartis, GSK and AbbVie. All other authors have no potential conflicts of interest to disclose. Funding StatementThis study was supported by the Personalized Health and Related Technologies (PHRT) grant of the ETH domain (PHRT - 521) to SS, and ETHZ and D-BIOL, and IMSB funding to B.S.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research project was carried out in accordance with the research plan and with principles enunciated in the current version of the Declaration of Helsinki (DoH), the Principles of Good Clinical Practice (GCP), the Swiss Law and Swiss regulatory authoritys requirements as applicable. Ethical approval was granted by the Ethics Committee of the Kanton Zurich (CEC Zurich, BASEC-Nr: 2018-01547).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesCNN training and test datasets are available at: https://doi.org/10.3929/ethz-b-000680077. RNA-seq measurements used in the study are available at the GEO repository at: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272681. The ex vivo response data will be made available upon request. Additional data generated in this study are not publicly available due to information that could compromise patient privacy or consent but are available upon reasonable request from the corresponding author.